Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03701581 · ClinicalTrials.gov registry record · Phase 2
4-aminopyridine Treatment for Nerve Injury
A Phase 2 study of Prostate Cancer and Nerve Injury, sponsored by John Elfar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT03701581: Recruiting Phase 2 study of Prostate Cancer and Nerve Injury, sponsored by John Elfar.
NCT03701581 is a Phase 2 study of Prostate Cancer and Nerve Injury that is actively recruiting participants, run by John Elfar. The registered enrollment target is 70 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03701581, a Phase 2 study of Prostate Cancer and Nerve Injury, is actively recruiting participants, sponsored by John Elfar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.
Primary Outcome
Incontinence measurement (change over time)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG 4-Aminopyridine
Study Locations (2)
Arizona
- University of Arizona - Tucson
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-06-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT03701581 shows while recruiting
NCT03701581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03701581 reports a single indexed study location in Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT03701581 about?
NCT03701581 is a clinical study titled "4-aminopyridine Treatment for Nerve Injury". To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.
What is the current status of trial NCT03701581?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-06-05. Estimated completion is 2028-12.
What conditions does trial NCT03701581 study?
This clinical trial studies the following conditions: Prostate Cancer, Nerve Injury.
What interventions are being tested in trial NCT03701581?
The interventions under investigation include: Placebo (OTHER), 4-Aminopyridine (DRUG).
Who is sponsoring clinical trial NCT03701581?
This trial is sponsored by John Elfar, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03701581 being conducted?
This trial has 2 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03701581's enrollment target sits among peer trials
70 400th of 735 higher than 333 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
- NCT02616302 · 70 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI